Besides, due to the significant benefits in clinical research, dual immunotherapy (nivolumab+CTLA-4 inhibitor ipilimumab) has been approved by the FDA for the first-line treatment of PD-L1-positive (≥1%) and EGFR- or ALK-negative adult metastatic NSCLC in 2020 [94]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.